

CURRICULUM VITAE

May 30, 2018

PERSONAL INFORMATION

Name: Jeannette Y. Lee, Ph.D.
Citizenship: U.S. Citizen
Home Address: 26 Talais Drive
Little Rock, Arkansas 72223
Phone: (501) 821-2185

RANK/TITLE

Professor
Department: Biostatistics
Business Address: University of Arkansas for Medical Sciences
4301 West Markham, #781
Little Rock, Arkansas 72205-7199
Phone: (501) 526-6712
(501) 320-7344
Fax: (501) 526-6729
E-mail: jylee@uams.edu

EDUCATION:

Year	Degree	Institution
1977	Ph.D., Biostatistics	Johns Hopkins University Baltimore, Maryland
1972	A.B., Mathematics	Boston University Boston, Massachusetts

ACADEMIC APPOINTMENTS:

Year	Rank/Title	Institution
05/08 – present	Professor	Department of Biostatistics College of Medicine University of Arkansas for Medical Sciences Little Rock, Arkansas
07/06 – 5/08	Professor	Department of Medicine
09/99 – 6/06	Research Professor	School of Medicine
03/86 – 9/99	Research Associate Professor	University of Alabama at Birmingham Birmingham, Alabama
06/84 – 09/85	Senior Biostatistician	Bristol-Myers Company
01/83 – 05/84	Research Biostatistician	Syracuse, New York
07/79 – 06/81	Assistant Professor	Division of Radiation Oncology
10/76 – 06/79	Instructor	School of Medicine Washington University St. Louis, Missouri

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 2

AWARDS/HONORS:

NIH Traineeship (1972 - 1976)

PROFESSIONAL SOCIETIES:

Society for Clinical Trials

Association of Cancer Center Biostatistics Directors

ADVISORY COMMITTEES/REVIEW COMMITTEES

External Advisory Committee for the Chronic Lymphocytic Leukemia Consortium,
University of California, San Diego (2000-present)

External Advisory Committee for the Lymphoma SPORE, Johns Hopkins University
(2003-2008)

NIH/NIAID, Division of AIDS, HIV Prevention Trials Data Safety Monitoring Board (2006-
2013)

NIH/NHLBI Data Safety and Monitoring Board, Sickle Cell Disease Clinical Research
Network (2008-2010)

NIH/NHLBI Data Safety and Monitoring Board, Sickle Cell Disease Investigational
Research Trials (2010-2014)

NIH/NCI Clinical Oncology Study Section (2003-2008)

Data Coordinating Center Sub-committee, Review of grant proposals submitted in
response to RFA-DK-07-003 Multi-disciplinary Approach to the Study of Chronic
Pelvic Pain (MAPP) Research Network (U01) (2008)

Reviewer, NIH/NHLBI Reviewer for Systolic Blood Pressure Intervention Trial (SPRINT)
Coordinating Centers (2008)

Reviewer, Journal of the American Medical Association (2007-present)

Reviewer, NIH/NIDDK Blood Pressure and Diagnosis (R01) (2008)

Reviewer, NIH/NCI Quick Trials on Imaging and Image-guided Interventions (2009-
2012)

Reviewer, Gynecologic Oncology Group, NIH/NCI (U10) (2009)

Reviewer, NIH/NIDDK Ancillary Studies (R01) (2009-present) NIDDK External Expert
Panel for Nerve Re-routing Protocol (2010-2012)

NIDDK External Expert Panel for STONE Study (2011-2012)

Member, NIH/NCI Subcommittee H, Review of NCI Cooperative Groups (2010-2011)

Member, NHLBI Sickle Cell Investigational Research Trials Data and Safety Monitoring
Board, 2010-present

Reviewer, NIDDK Multicenter Clinical Trials Review, 2012

Reviewer, NIDDK Lower Urinary Tract Dysfunction Network review, 2012

Reviewer, Patient-Centered Outcomes Research Institute (PCORI) review, phase I,
2012

External Expert Panel, NIDDK FL3X: An Adaptive Intervention to Improve Outcomes for
Youth with Type 1 Diabetes, 2012-present

Reviewer, NIDDK Lower Urinary Tract Dysfunction Network expansion, 2013.

Reviewer, NIDDK U34 Grant Review, 2013.

Reviewer, NIAID AIDS Clinical Trials Group Review, 2013.

Reviewer, NIDDK U01 Grant Review, 2013.

Reviewer, NIDDK T32 Grant Review, 2013.

Reviewer, NIDDK U01 Grant Review, 2014.

Reviewer, NIDDK LURN Grant Review, 2014.

Reviewer, NCI, NCORP Grant Review, 2014.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 3

Reviewer, NIDDK, T32 Grant Review, 2014.
Reviewer, NIDDK, R01 Grant Review, 2014.
Reviewer, NIDDK, R03 Grant Review, 2015.
External Expert Panel, NIDDK, Urinary Stone Disease Research Network (USDRN),
2016-present
Reviewer, NIAID, Clinical Trial Implementation R01 Grant Review, 2017.
Reviewer, NIDDK, R01 Review, 2017.
Reviewer, NIAMS, R15 Review, 2018.

UNIVERSITY ACTIVITIES:

UAMS Cancer Center Senior Leadership Committee (2008-present)
UAMS Breast Cancer Executive Committee (2009-present)
Chair, Protocol Review and Monitoring Committee, Winthrop P. Rockefeller Cancer
Institute, UAMS (2011-2017)
Chair, UAMS, Biostatistics Department Promotion and Tenure Committee (2013-2016)
Member of the College of Medicine Dean's Distinguished Lecture, Faculty Scholar and
Alumnus Selection Committee (2015 – present)
Member of the College of Medicine's Promotion and Tenure Committee (2016-present)

MAJOR RESEARCH INTERESTS:

Design of clinical trials
Survival analysis

GRANT SUPPORT (Current):

1. U24OD024957 (PIs: Jeannette Lee and Jessica Snowden). Data Coordinating and Operations Center (DCOC) for the IDeA States Pediatric Clinical Trials Network. Funding period: 9/21/2016 to 8/30/2020. Role: Principal investigator (MPI).
2. UM1CA121947/UCLA (UAMS PI: Jeannette Y. Lee, PI: Ronald Mitsuyasu). AIDS-Associated Malignancies Clinical Trials Consortium (AMC), Funding Period: 8/29/2006 to 8/31/2020. Role: Director, Statistical Center
3. HHSN2722013/UAB (UAMS PI: Jeannette Y. Lee, PI: Edward Hook). Sexually Transmitted Infections Clinical Trials Group Infrastructure: Task Area 1, Task Order 11. Funding period: 9/15/2016 – 9/14/2018. Role; Member, Executive Committee and Scientific Review Committee.
4. HHSN2722013/UAB (UAMS PI: Jeannette Y. Lee, PI: Edward Hook). Sexually Transmitted Infections Clinical Trials Group Task Area 2, Task Order 5: Study to compare efficacy of azithromycin between symptomatic and asymptomatic men with chlamydia in a youth correctional facility. Funding period: 8/1/2015 – 12/14/2019. Role; Study Statistician.
5. U01AI108509/UAB (UAMS PI: Jeannette Y. Lee, PI: Jane Schwebke) Randomized Clinical Trial of Treatment of male partners of women with bacterial vaginosis (BV). Role: Director, Statistical and Data Management Center, 7/17/2014 – 6/30/2019.

GRANT SUPPORT (Past):

1. R01AI093692/UAB (UAMS PI: Jeannette Y. Lee, PI: William Geisler). Mechanisms and correlates of immune protection in genital chlamydia, Role: study statistician, 12/2011-11/2016.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 4

2. SIP 14-034/UAB Prospective Study of Immune Response to Chlamydial Infection (Centers for Disease Control), (UAMS PI: Jeannette Lee; PI: William Geisler). Role: Study statistician. 9/1/2014 – 8/31/2017.
3. U01 DK063788/UAB Data Coordinating Center for Benign Prostate Symptoms, Role: Principal Investigator (10/2002 – 5/2008) Biostatistician (6/2008 –6/2012)
4. W81XWH-05-1-0615 (Department of Defense) Neurofibromatosis, Role: Principal Investigator (8/2005 – 5/2008) Consultant (6/2008 – 6/2012)

TEACHING ACTIVITIES:

1. K30HL004146 (PI: Larry Moreland) Clinical Research Training Program at UAB 2000-2008. Role: Co-leader, Module on Epidemiology and Biostatistics; Curriculum Committee Member; Admission Committee Member; Lecturer for the following lectures:
 - a. Design of Clinical Trials
 - b. Analysis and outcome measurements
 - c. Biostatistics FAQs, considerations and responses to summary statements
 - d. Data Safety and Monitoring
 - e. Statistical Analysis Methods
2. UAMS Hematology Oncology Fellow Lectures
 - a. Design of Clinical Trials - Outcome Measures (July 2009)
 - b. Clinical Research – Outcome Measures and Data Monitoring (July 2009)
 - c. Statistical Analysis Methods for Clinical Oncology (October 2009)
 - d. Discussant - Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic CRC treated with Cetuximab (November 2009)
 - e. Cancer Clinical Trials (March 2012)
 - f. Cancer Clinical Trials (May 2013)
3. UAMS Neurology Resident Lecture – Introduction to Medical Statistics (October 2013)
4. Winthrop Rockefeller Cancer Institute
 - a. Why do patients rarely enroll in clinical trials? (September 2008)
 - b. Clinical Trial Enrollment: A Multi-factor Process (July 2009)
5. Mentoring
 - a. Enderlin, Carol, UAMS School of Nursing “A Tailored Insomnia Intervention for Women over 50 with Non-metastatic Breast Cancer” (2008-present)
 - b. Goodwin, Julie. Multiple Myeloma QOL, chemotherapy-induced peripheral neuropathy and gene expression. CCTR submission, 2009-present
 - c. Kvale, Elizabeth, UAB School of Medicine, K23AG031346, Cognitive intervention for speed of processing in older cancer survivors (2006-2008).
 - d. King, Jennifer, UAB School of Medicine, K23AI074390. Impact of menstrual cycle on antiretroviral pharmacokinetics (2006-2008).
 - e. Stephen W. Erickson, Ph.D., UAMS School of Medicine, Department of Biostatistics (2011-present)
 - f. Shasha Bai, Ph.D., UAMS School of Medicine, Department of Pediatrics, Division of Biostatistics (2014-present).

BIBLIOGRAPHY

PEER-REVIEWED MANUSCRIPTS - PUBLISHED/IN PRESS:

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 5

1. Ortvals DW, Kiebhaber H, Presant CA, Amburg AL Van, **Lee JY**: Influenza immunization of adult patients with malignant diseases. *Ann Int Med* 87:522-556, 1977.
2. Goldring D, Hernandez A, Choi S, **Lee JY**, Londe S, Lindgren F, Burton R: Blood pressures in a high school population: Clinical profile of the juvenile hypertension. *Pediatrics* 95:298-304, 1979.
3. **Lee JY**, Marks JE, Simpson JR: Recruitment of patients to a cooperative group clinical trial. *Cancer Clin Trials* 3:381-384, 1980.
4. Meyer JS, **Lee JY**: Relationships of S-phase fraction of breast carcinoma in relapse to remission-duration, estrogen receptor contents, therapeutic responsiveness and duration of survival. *Cancer Res* 40:1890-1895, 1980.
5. Martin SA, Marks JE, **Lee JY**, Bauer WC, and Ogura JH: Carcinoma of the pyriform sinus: Predictors of TNM relapse. *Cancer* 46:1974-1981, 1980.
6. Bedwinek JM, Fineberg BB, **Lee JY**, Ocwieza MA: Analysis of failures following radiotherapy for isolated local-regional recurrence of breast cancer. *Int J Radiat Oncol Biol Phys* 7:581-585, 1981.
7. Bedwinek JM, **Lee JY**, Fineberg BB, Ocwieza MA: Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. *Cancer* 47:2232-2235, 1981.
8. **Lee JY**, Perez CA: A radiation oncology oriented anatomico-pathological classification system. *Int J Radiat Oncol Biol Phys* 7:813-815, 1981.
9. **Lee JY**: A statistical note: Selection of an endpoint. *Cancer Clin Trials* 5:261-265, 1982.
10. **Lee JY**, Bedwinek JM Fineberg BB, and Ocwieza MA: Alternative approaches to evaluating the impact of local control on survival. *Cancer Clin Trials* 5:281-284, 1982.
11. **Lee JY**, Perez CA, Ettinger N, Fineberg BB: The risk of second primaries subsequent to irradiation for cervix cancer. *Int J Radiat Oncol Biol Phys* 8:207-211, 1982.
12. **Lee JY**, Marks JE, Simpson JR: Age as a criterion for eligibility in a lung cancer clinical trial. *Cancer Clin Trials* 5:449-452, 1982.
13. Bedwinek J, Rao DV, Perez C, **Lee J**, Fineberg B: Stage III and localized stage IV breast cancer: Irradiation alone versus irradiation plus surgery *Int J Radiat Oncol Biol Phys* 8:31-36, 1982.
14. Rao DV, Bedwinek JM, Perez CA, **Lee JY** and Fineberg BB: Stage III carcinoma of the breast: Analysis of prognostic factors. *Cancer* 50:2037-2043, 1982.
15. **Lee JY**, Breaux SR: Accrual of radiation therapy patients to clinical trials. *Cancer* 52:1014-1016, 1983.
16. Thomas PRM, **Lee JY**, Fineberg BB, Razek AA, Perez CA, Land VJ, Vietti TJ: An analysis of neuroblastoma at a single institution. *Cancer* 53:2079-2082, 1984.
17. Manu P, Runge LA, **Lee JY**, Oppenheim AD: Judged frequency of serious complications after "invasive" diagnostic procedures: Systematic biases of a physician population. *Med Care* 22:366-370, 1984.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 6

18. Mill WB, Baglan RJ, Kurichety P, Prasad S, **Lee JY**, Moller R: Symptomatic radiation-induced pericarditis in Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 10:2061-2065, 1984.
19. Berland LL, Koslin DB, Kenney PJ, Stanley RJ, **Lee JY**: Differentiation of benign from malignant adrenal masses using dynamic contrast enhanced CT criteria. *AJR Am J Roentgenol* 151:95-102, 1988.
20. Silvey L, Carpenter JT, Wheeler RH, **Lee J**, Conolley C: A randomized comparison of halperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy in breast cancer. *J Clin Oncol* 6:1397-1400, 1988.
21. Berland LL and **Lee JY**: Comparison of contrast media injection rates and volumes for hepatic dynamic incremented CT. *Invest Radiol* 23:918-922, 1988.
22. LoBuglio AF, Saleh M, **Lee J**, Khazaeli MB, Carrano R, Holden H and Wheeler R: Phase I Trial of repetitive large doses of murine monoclonal antibody 17-1A I. Clinical Aspects. *J Natl Cancer Inst* 80:932-936, 1988.
23. LoBuglio AF, Khazaeli MB, **Lee J**, Haynes A, Sumerel L, Mischak R and Spittler L: Pharmacokinetics and immune response to xomazyme - mel in melanoma patients. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 1:305-310, 1988.
24. **Lee JY** and Soong S-j: An overview of Alabama cancer mortality among whites: 1950-1980. *Ala J Med Sci* 25:375-382, 1988.
25. Ryan WG, Richards JM and **Lee JY**: Characteristics of the in vivo RBC: Plasma lithium ratio in a clinical setting. *Biol Psychiatry* 26:537-540, 1989.
26. Saleh MN, Moore DL, **Lee JY**, and LoBuglio AF: Monocyte-platelet interaction in immune and non-immune thrombocytopenia. *Blood* 74(4):1328-1331, 1989.
27. Oberman A, Fan P-H, Nanda NC, **Lee JY**, Huster WJ, Sulentic JA and Storey OF: Reproducibility of two-dimensional exercise echocardiography. *J Am Coll Cardiol* 14:923-928, 1989.
28. **Lee JY** and Soong S-j: Cancer mortality in the South: 1950-1980. *South Med J* 83(2):185-190, 1990.
29. Kim RY, Spencer SA, Meredith RF, Weppelmann B, **Lee JY**, Smith JW and Salter MM: Extradural spinal cord compression: analysis of factors determining functional prognosis - a prospective study. *Radiology* 176(1):279-282, 1990.
30. Dismukes WE, Wade JS, **Lee JY**, Dockery BK and Hain JD: Nystatin therapy of candidiasis hypersensitivity syndrome: results of a prospective, randomized clinical trial. *N Engl J Med* 323(25):1717-1723, 1990.
31. Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, **Lee JY** and Khazaeli MB: A Phase II trial of murine monoclonal antibody 17-1A and γ -IFN-Clinical and Immunologic data. *Cancer Immunol Immunother* 32:185-190, 1990.
32. Trotti A, Weppelman B, Kim R, **Lee J**, and Salter M: Results of custom surface applicators in cancers of the oral cavity and oropharynx. *Endocurie Hyperthermia* 6:143-151, 1990.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 7

33. Saleh MN, Wheeler RH, **Lee JY**, Khazaeli MB, Unger MW, Russell CH and LoBuglio AF: ¹¹¹In-Labeled monoclonal anti-CEA antibody (ZCE025) in the immunoscintigraphic imaging of metastatic CEA producing adenocarcinomas. *Clin Nucl Med* 16(2):110-116, 1991.
34. Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, Macdonald J, De Conti RC, and **Lee J**: A randomized trial to compare intravenous and orally-administered etoposide in combination with cisplatin for the treatment of small cell cancer. *Cancer* 67 (1Supp):245-249, 1991.
35. Mulligan SA, Matsuda T, Lanzer P, Gross GM, Routh WD, Keller FS, Koslin DB, Berland LL, Fields MD, Doyle M, Cranney G, **Lee J** and Pohost G: Prospective comparison of MR angiography and colon duplex ultrasound with conventional angiography for peripheral arterial occlusive disease. *Radiology* 178(3):695-700, 1991.
36. Ruckdeschel JC, Moores D, **Lee JY**, Einhorn LH, Mandelbaum I, Weiss GR, Koeller J, Losada M and Keller J: Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. *Chest* 100:1528-1535, 1991.
37. Soong S-j, Shaw HM, Balch CM, McCarthy WH, Urist MM, and **Lee JY**: Predicting survival and recurrence in localized melanoma: a multivariate approach. *World J Surg* 16:191-195, 1992.
38. Harmon BH, Berland LL and **Lee JY**: Effect of varying rates of low-osmolarity contrast media injection for hepatic CT: correlation with indocyanine green transit time. *Radiology* 184(2):379-82, 1992.
39. Modell JG, Mountz JM, Glaser FB and **Lee JY**: Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. *Alcoholism* 17(2):234-40, 1993.
40. Robert F, Mignucci M, McCurdy SA, Maldonado N, and **Lee JY**: Hemostatic abnormalities associated with monoclonal gammopathics. *Am J Med Sci* 306(6):359-366, 1993.
41. Modell JG, Taylor JP and **Lee JY**: Breath-alcohol values following mouthwash use: is it safe to swish and drive? *JAMA* 270:2955-2956, 1993.
42. **Lee JY**, Oberman A, Fletcher GF, Raczynski JM, Fletcher BJ, Nanda NC and Jensen BE: Design of the Training Levels Comparison Trial. *Control Clin Trials* 15:59-76, 1994.
43. Denning DW, **Lee JY**, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy of invasive aspergillosis. *Am J Med* 97:135-144, 1994.
44. **Lee JY**: Uses of clinical databases. *Am J Med Sci* 308:58-62, 1994.
45. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, **Lee JY**, Koopman WJ, Krumdieck CL and Alarcon GS: Supplementation with folic acid during methotrexate therapy of rheumatoid arthritis: results from a double-blind, placebo-controlled trial. *Ann Intern Med* 121 (11):833-841, 1994.
46. Weinsier R, Wilson LJ and **Lee JY**: Medically safe rate of weight loss: a guideline based on the currently available data. *Am J Med* 98(2):115-7, 1995.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 8

47. Oberman A, Fletcher GF, **Lee J**, Nanda N, Fletcher BJ, Jensen BE and Caldwell ES: Efficacy of high intensity exercise training on left ventricular ejection fraction in men with coronary heart disease: the Training Levels Comparison Study. *Am J Cardiol* 76(10):643-7, 1996.
48. **Lee JY**, Jensen BE, Oberman A, Fletcher GF, Fletcher BJ and Raczynski JM: Adherence in the Training Levels Comparison Trial. *Med Sci Sports* 28(1):47-52, 1996.
49. Kusek JW, **Lee JY**, Charleston J, Faulkner M, Levell B, Milligan S and Norris K: Participant satisfaction in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 17:47S-54S, 1996.
50. **Lee JY**, Greene PG, Douglas M, Grim C, Kirk KA, Milligan S, Smith DE and Whelton PK: Appointment attendance, pill counts and achievement of target blood pressure in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 17:17S-33S, 1996.
51. Wright JT Jr, Kirk KA, Kusek JW, Toto R, **Lee JY**, Agodoa LY, Randall OS and Glasscock R: Design of the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 17:3S-16S, 1996.
52. **Lee J**, Bernhard S, Douglas M, Greene P, Kusek J, Norris K and Whelton P: Assessing medication adherence in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Am J Hypertens* 9:719-725, 1996.
53. Whelton PK, **Lee JY**, Kusek JW, Charleston J, Debruge J, Douglas M, Faulkner M, Greene P, Jones C, Kiefer S, Kirk KA, Levell B, Norris K, Powers S, Retta TM, Smith DE, and Ward H: Recruitment in the African American Study of Kidney Disease and Hypertension. *Control Clin Trials* 17:34S-39S, 1996.
54. Kusek JW, **Lee JY**, Smith DE, Milligan S, Faulkner M, Cornell CM, Kopple J and Greene PG: Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 17:40S-46S, 1996.
55. Jensen BE, Fletcher BJ, Rupp JC, Fletcher GF, **Lee JY** and Oberman AL: Training level comparison study: Effect of high and low intensity exercise on ventilatory threshold in men with coronary artery disease. *J Cardiopulm Rehabil* 16(4):227-32, 1996.
56. Figueroa-Colon R, Franklin FA, Goran MI, **Lee JY** and Weinsier RL: Reproducibility of resting energy expenditure in prepubertal girls. *Am J Clin Nutr* 64(4):533-6, 1996.
57. Knoll GA, Tankersley MR, **Lee JY**, Julian BA and Curtis JJ: The impact of renal transplantation on survival in Hepatitis C positive end-stage renal disease patients. *Am J Kidney Dis* 29(4):608-14, 1997.
58. Meredith RF, Salter MM, Kim RY, Spencer SA, Weppelmann B, Rodu B, Smith JW and **Lee JY**: A randomized trial evaluation of sucralfate for radiation mucositis. *Int J Radiat Oncol Biol Phys* 37(2), 275-279, 1997.
59. Figueroa-Colon R, Franklin FA, **Lee JY**, von Almen TK, and Suskind RM: Feasibility of a clinic-based hypocaloric dieting intervention implemented in a school setting for obese children. *Obes Res* 4(5):419-29, 1996.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 9

60. Morgan SL, Anderson AM, Hood SM, Matthews PA, **Lee JY**, and Alarcon GS: Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis. *Arthritis Care Res* 10(1):9-17, 1997.
61. Figueroa - Colon R, Franklin FA, **Lee JY**, Aldridge R, Alexander L: Prevalence of obesity with increased blood pressure in elementary school-aged children. *South Med J* 90(8):806-13, 1997.
62. Stevens DA and **Lee JY**: Analysis of compassionate use itraconazole therapy of invasive aspergillosis by the NIAID Mycoses Study Group. *Arch Intern Med*, 157:1857-1862, 1997.
63. Ayar D, Golla B, **Lee JY** and Nath H: Needle track metastasis following transthoracic needle biopsy. *J Thorac Imaging*, 13:2-6, 1998.
64. Julian BA, Brantley RR Jr, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JY and Prchal JT: Losartan, an angiotensin II type I receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. *J Am Soc Nephrol* 9:1104-1108, 1998.
65. Morgan SL, Baggott JE, **Lee JY** and Alarcon GS: Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low-dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. *J Rheumat* 25:441-446, 1998.
66. El Gammal T, Sobol W, Wadlington VR, Sillers MJ, Crews C, Fisher III WS and **Lee JY**: Cerebrospinal fluid fistula detected by magnetic resonance cisternography. *Am J Neuroradiol* 19:627-631, 1998.
67. Thomas CJ, Pappas PG, Bradley ME, **Lee JY**, Klug LA, Gillespie RW, Dill SR and Pinner RW: Surveillance of Cryptococcosis in Alabama, 1992-1994. *Ann Epidemiol* 8 (4):212-16, 1998.
68. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DA, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, **Lee JY**, Dismukes WE: A prospective multicenter surveillance study of funguria in hospitalized patients. *Clin Infect Dis* 30:14-8, 2000.
69. Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, **Lee J**, Thomas C. Candiduria – A randomized, double blind study of treatment with fluconazole and placebo. *Clin Infect Dis* 30:19-24, 2000.
70. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, **Lee JY**, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS, Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. *Nat Med* 4(11):1302-7, 1998.
71. O'Sullivan CE, Drew WL, McMullen DJ, Miner R, **Lee JY**, Kaslow RA, Lazar JG, Saag MS. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. *J Infect Dis*. 180 (3):847-9, 1999
72. Saag MS, Fessel WJ, Kaufman C, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, **Lee J**, Brenner-Gati L, Klausner M. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. *AIDS Res Hum Retroviruses* 15 (16):1413-1417, 1999.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 10

73. Stevens DA, Schwartz HJ, **Lee JY**, Moskowitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon CU, Judson MA, Platts-Mill TAE and DeGraff AC, Jr.: A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. *N Engl J Med* 342:756-62, 2000.
74. Ratner L, **Lee J**, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B and Straus D for the AIDS Malignancy Consortium. Chemotherapy for HIV-associated non-Hodgkin's Lymphoma in Combination with Highly Active Antiretroviral Therapy. *J Clin Oncol* 19(8):2165-2170, 2001.
75. Kim JR, Oberman A, Fletcher GF, **Lee JY**. Effect of exercise intensity and frequency on lipid levels in men with coronary heart disease: Training Level Comparison Trial. *Am J Cardiol* 87(8): 942-6, 2001.
76. Eubanks V, Koppersmith N, Wooldridge N, Clancy JP, Lyrene R, Arani RB, **Lee J**, Moldawer L, Atchison J, Sorscher EJ, Makris CM. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. *J Pediatr* 140(4):439-44, 2002.
77. Miles SA, Dezube BJ, **Lee JY**, Fletcher MA, Saville MW, Kaplan LD, Groopman J, Scadden DT, Cooley T, Krown SE, Von Roenn J, Friedman-Kien A for the AIDS Malignancy Consortium. Anti-tumor activity of oral 9-*cis* retinoic acid in HIV infected patients with Kaposi's sarcoma: a multicenter trial of the AIDS Malignancy Consortium. *AIDS* 16:421-429, 2002. PMID11834954
78. Cianfrocca M, Cooley TP, **Lee JY**, Rudek MA, Ratner L, Pluda JM, Figg WD, Krown SE and Dezube BJ. Matrix Metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS Malignancy Consortium Study. *J Clin Oncol* 20:153-159, 2002.
79. Perfect JR, Cox GM, **Lee JY**, Kauffman CA, de Repentigny L, Chapman SW, Morrison VA, Pappas P, Hiemenz JW and Stevens DA and the NIAID-sponsored Mycoses Study Group. The impact of culture isolation of aspergillus: a hospital-based survey of aspergillosis. *Clin Infect Dis* 33:1824-33, 2001.
80. Walsh TJ, Pappas PG, Winston D, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, and **Lee J** for the NIAID Mycoses Study Group. Voriconazole versus liposomal amphotericin B for the empirical antifungal therapy in persistently febrile neutropenic patients: a prospective, randomized, multicenter, international trial. *N Engl J Med* 346(4):225-234, 2002.
81. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edward JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, **Lee J**, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Robin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu T-C, Panzer H, Rosenstein RB, Booth J for the NIAID Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. *Clin Infect Dis* 36:1221-1228, 2003.
82. Pappas PG, Rex JH, **Lee J**, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE and the NIAID

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 11

- Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis*, 37(5):634-43, 2003.
83. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, **Lee J.** for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Candidiasis Subproject. Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. *Antimicrob Agents Chemother*, 47(10):3149-54, 2003.
 84. Bennett JE, Kauffman C, Walsh T, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, **Lee J**, Pappas P, Powers J, Rex J, Verweij P, Viscoli C. Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. *Clin Infect Dis*, 36(Suppl 3):S123-7, 2003.
 85. Bennett JE, Powers J, Walsh T, Viscoli C, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, **Lee J**, Pappas P, Rex J, Verweij P. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. *Clin Infect Dis*, 36(Suppl 3):S117-22, 2003.
 86. Bennett JE, Powers J, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, **Lee J**, Pappas P, Rex J, Verweij P, Viscoli C, Walsh T. Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. *Clin Infect Dis*, 36(Suppl 3):S113-6, 2003.
 87. Morgan, SL, Abercrombie, W, **Lee JY.** Need for precision studies at individual institutions and assessments of size of regions of interest on serial DXA scans. *J Clin Densitom* 6(2): 97-101, 2003.
 88. Van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, **Lee J**, Walsh TJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. *Clin Infect Dis* 39(10):1407-16, November 15, 2004.
 89. Morgan SL, Oster R, **Lee JY**, Alarcon, GS, Baggott JE. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. *Arthritis Rheum* 50(10):3104-3111, October 2004.
 90. Noy A, David DR, **Lee J**, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S and Gill P: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's Sarcoma in a phase III trial, but highlights sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 study team. *J Clin Oncol* 23(5): 1-9, February 10, 2005.
 91. Woodberry T, Henry LM, O'Connor PG, Davis JK, Suscovich TJ, Martin JN, Osmond D, Kedes DH, **Lee J**, Walker BD, Scadden DT, Brander C. Impact of HIV co-infection and viral loads on the detection of cytotoxic T-lymphocyte responses to Kaposi's sarcoma associated herpesvirus (KSHV/HHV8) LANA (ORF-73) and ORF-65 proteins. *J Infect Dis* 192(4): 622-9, 2005.
 92. Kaplan LD, **Lee JY**, Ambinder RJ, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT: Rituximab does not improve clinical outcome in a randomized phase III

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 12

- trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma. *Blood* 106(5): 1538-1543, 2005. PMC1895225
93. Rostand SG, Cross SK, Kirk KA, **Lee JY**, Kuhlmann A, Amann K: Racial differences in renal arteriolar luminal diameter are independent of blood pressure. *Kidney Int* 68(3): 1154-1160, 2005.
 94. Robbin ML, Oser RF, **Lee JY**, Heudebert GR, Mennemeyer ST, Allon M: Randomized clinical trial comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes. *Kidney Int* 69: 730-735, 2006.
 95. Krown SE, **Lee JY**, Lin L, Fischl MA, Ambinder R, Von Roenn JH. Interferon alfa-2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi's sarcoma: an AIDS Malignancy Consortium Phase I Trial. *J Acquir Immune Defic Syndr* 41:149-53, 2006.
 96. Dezube BJ, Krown SE, **Lee JY**, Bauer KS, Aboulafia DM. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a randomized phase II AIDS Malignancy Consortium Study. *J Clin Oncol* 24:1389-1394, 2006.
 97. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Cost M, Darragh T, **Lee JY**. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. *AIDS* 20(8): 1151-1155, 2006.
 98. Hogg RJ, **Lee J**, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette C, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio J, Holub BJ. Placebo-controlled clinical trial evaluating omega-3 fatty acids and alternative day prednisone in patients with IgA nephropathy. *Clin J Am Soc Nephrol* 1: 467-74, 2006.
 99. Moldoveanu Z, Wyatt RJ, **Lee J**, Tomana M, Julian BA, Mestecky J, Huang W-Q, Anreddy SR, Hall S, Hastings C, Lau KK, Cook WJ and Novak J. Patients with IgA nephropathy have increased serum levels of galactose-deficient IgA. *Kidney Int* 71:1148-54, 2007.
 100. Lau K, Wyatt R, Moldoveanu Z, Tomana M, Julian B, Hogg R, **Lee J**, Huang W-Q, Mestecky J, Novak J. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. *Pediatr Nephrol* 22(12):2067-2072, 2007.
 101. Brinker BT, Krown SE, **Lee JY**, Cesarman E, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH. Phase I/II Trial of BMS-275291 in patients with HIV-related Kaposi's sarcoma. A Multicenter Trial of the AIDS Malignancy Consortium. *Cancer* 112: 1083-8, 2008.
 102. Stier EA, Goldstone SE, Berry M, Panther LA, Jay N, Krown SE, **Lee J**, Palefsky JM. Infrared coagulator for treatment of anal high grade squamous intraepithelial neoplasia in HIV infected individuals: a pilot study. *J Acquir Immune Defic Syndr* 47(1): 56-61, 2008.
 103. Mullins C, Lucia MS, Hayward SW, **Lee JY**, Levitt JM, Lin V, Liu BCS, Rubin MA, Slawin K, Star RA and Getzenberg RH for the MPSA Consortium. A Comprehensive Approach toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium. *J Urol* 179 (4):1243-56, 2008.
 104. Spitzer TR, Ambinder RF, **Lee JY**, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide and autologous stem cell

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 13

- transplantation for HIV-associated lymphoma: AIDS Malignancy Consortium Study 020. *Biol Blood Marrow Transplant* 14(1): 59-66, Jan 2008.
105. Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Suryanawashi S, **Lee JY**, Rotonda J, Kusek JW, Nyberg LM. Long-term treatment with finasteride results in a clinical significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. *J Urol* 180(3): 1030-2, Sep 2008.
 106. Krown SE, **Lee JY**, Dittmer DP. More on HIV-associated Kaposi's sarcoma. *N Engl J Med* 358(5): 535-6, Jan 2008. PMC2857919
 107. Lin L, **Lee JY**, Kaplan LD, Dezube BJ, Noy A, Krown SE, Levine AM, Yu Y, Hayward GS, Ambinder RF: Chemotherapy in AIDS-Associated Lymphoma Leads to Disappearance of KSHV DNA from Blood. *J Clin Oncol* 27(15): 2496-2502, May 2009. PMC2684854
 108. Schwebke JR, River C, **Lee J**: Prevalence of Gardnerella vaginalis in male sexual partners of women with and without bacterial vaginosis. *Sex Transm Dis* 36(2):92-4, Feb 2009.
 109. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, **Lee J**, Ambinder R, Campbell N, Lairmore M: Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. *PLOS One* 4(2) epub Feb 2, 2009. PMC2636875
 110. Chadburn A, Chiu A, **Lee JY**, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium Clinical Trials 010 and 034. *J Clin Oncol* 27(30):5039-48, Oct 2009. PMC2799056
 111. Kvale E, Murthy R, Taylor R, **Lee JY**, Nabors LB. Distress and quality of life in primary high grade brain tumor patients. *Supportive Care in Cancer* 17(7):793-799, July 2009.
 112. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chathan WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, **Lee JY**, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. *J Clin Invest* 119(6):1668-77, June 2009. PMC2689118
 113. Sparano JA, **Lee J**, Kaplan LD, Levine A, Harrington W Jr, Ambinder R, Wachsman W, Aboulafia D, Noy A, Henry D, Von Roenn J, Dezube B, Remick S, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective without excessive toxicity in HIV-associated, B-cell non-Hodgkin's Lymphoma. *Blood* 115(15):3008-16, April 2010. PMC2858478.
 114. **Lee JY**, Andriole G, Avins A, Crawford ED, Foster H, Kaplan H, Kreder K, Kusek JW, McCullough A, McVary K, Meleth S, Naslund M, Nickel JC, Nyberg L, Roehrborn C, Williams OD, Barry MJ. Redesigning a large-scale clinical trial in response to negative external trial results: The CAMUS study of Phytotherapy for Benign Prostatic Hyperplasia. *Clin Trials* 6: 628-636, December 2009. PMC3082919

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 14

115. Lechowicz MJ, Dittmer DP, **Lee JY**, Krown SE, Wachsman W, Aboulafia D, Dezube BJ, Ratner L, Said J, Ambinder RF: Molecular and clinical assessment in the treatment of AIDS Kaposi's Sarcoma with valproic acid. *Clin Inf Dis* 49: 1946-1949, December 2009. PMC3017346
116. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, **Lee JY**, Krown SE, Sparano JA: Randomized Trial of Paclitaxel versus Pegylated Liposomal Doxorubicin for Advanced Human Immunodeficiency Virus-associated Kaposi's sarcoma: Evidence for Symptom Palliation from Chemotherapy. *Cancer* 116(16): 3969-77, August 2010. PMC3157242
117. Badgwell B, Pierce C, Broadwater JR, Westbrook K, Korourian S, Davis D, Hiatt K, **Lee J**, Cheung WL, Klimberg VS. Intraoperative sentinel lymph node analysis in melanoma, *J Surg Onc* 103(1):1-5, January 2011.
118. Koon HB, Fingleton B, **Lee JY**, Geyer JT, Cesarman E, Parise RA, Egorin MJ, Dezube BJ, Aboulafia D, Krown SE: Phase II trial of topical halofuginone in patients with HIV-related Kaposi's Sarcoma, a multicenter trial for the AIDS Malignancy Consortium. *J Acquir Def Syndr* 56(1): 64-84, January 2011. PMC3017346
119. Wilkin T, **Lee JY**, Lensing SY, Stier EA, Goldstone SE, Berry MJ, Jay N, Aboulafia D, Cohen DL, Einstein MK, Mitsuyasu RT, Palefsky JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. *J Infect Dis* 202(8):1246-53, October 2010. PMC3118428.
120. Schwebke JR, Rompalo A, Taylor S, Seña AC, Martin DH, Lopez LM, Lensing S, **Lee JY**. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens – a randomized clinical trial. *Clin Inf Dis* 52:163-170, January 2011. PMC3106252.
121. Kaplan SA, **Lee JY**, Meehan AG, Kusek JW. Long-term treatment with finasteride resulted in a significant improvement relative to placebo in clinical progression of BPH in men with enlarged prostates (≥ 30 ml), but not in those with smaller prostates (< 30 ml). *J Urology* 185: 1369-73, April 2011.
122. **Lee JY**, Foster HE Jr, McVary KT, Meleth S, Stavris K, Downey J, Kusek JW. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. *J Alt Comp Med* 17(5): 1-4, May 2011. PMC3155098
123. Wagner-Johnston ND, Gellert L, Gocke CD, Lemas MV, **Lee J**, Martinez-Maza O, Ambinder RF: Clonal immunoglobulin DNA in the plasma of patients with AIDS-lymphoma. *Blood* 117 (18): 4860-2, May 2011. PMC3100695.
124. Martin MY, Pisu M, Oster RA, Urmie JG, Schrag D, Huskamp H, **Lee J**, Kiefe C, Fouad M: Racial variation in willingness to trade financial resources for life prolonging cancer treatment. *Cancer* 117(15):3476-84, Aug 2011. PMC3142305.
125. Barry MJ, Meleth S, **Lee JY**, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole G, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT. Effect of increasing doses of saw palmetto on lower urinary tract symptoms. *JAMA* 306(12): 1344-1351, September 2011. PMC3326341.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 15

126. McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, **Lee JY**, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. *J Clin Invest* 121(10): 3991-4002, Oct 2011. PMC3195458
127. Lee JY, Moore PC, Lensing SY. Impact of HIV Infection on Medicare Beneficiaries with Lung Cancer. *J Ca Epi*, Epub April 2, 2012. PMC3324136.
128. Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, Venkataramanan R, Han K, Cesarman E, Dittmer DP. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi Sarcoma: an AIDS Malignancy Consortium Study. *J Acquir Immune Defic Syndr* 59(5):447-454, April 2012. PMC3302934
129. **Lee JY**, Lensing SY, Schwebke JS. Retention of Clinical Trial Participants in a Study of Nongonococcal Urethritis (NGU), a Sexually Transmitted Infection in Men. *Contemp Clin Trials* 33(4):606-610, July 2012. PMC3346855
130. Barta SK, **Lee JY**, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS-Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin's lymphoma. *Cancer* 118(16):3977-83, August 2012. PMC3310940
131. Seña AC, Lensing S, Rompalo A, Taylor S, Martin DA, Lopez LM, **Lee JY**, Schwebke JR. *Chlamydia trachomatis*, *Mycoplasma genitalium* and *Trichomonas vaginalis* infections in symptomatic men with non-gonococcal urethritis: predictors of infection and persistence after therapy. *J Inf Dis* 206(3):357-365, August 2012. PMC3490700
132. Wilson M, Korourian S, Boneti C, Adkins L, Badgwell B, Lee J, Klimberg VS. Long-term results of excision followed by radiofrequency ablation as the sole means of local therapy for breast cancer. *Ann Surg Oncol* 9(10):3192-8, Oct 2012.
133. Helfand BT, Lee JY, Sharp V, Foster H, Naslund M, Williams OD, McVary KT for the CAMUS Study Group. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. *J Urol* 188(6):2288-93, December 2012.
134. Levine AM, Noy A, **Lee JY**, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Liposomal doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone (DR-COP) in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. *J Clin Oncol* 31(1):58-64, January 1, 2013. PMC3530691
135. Catalano PJ, Ayanian JZ, Weeks JC, Kahn KL, Landrum MB, Zaslavsky A, Lee J, Pendergast J, Harrington DP: Representativeness of participants in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium relative to the Surveillance, Epidemiology and End Results (SEER) Program. *Medical Care* 51(2):e9-e15, February 2013. PMC3654676
136. Fouad MN, **Lee JY**, Catalano PJ, Vogt TM, Zafar SY, West DW, Simon C, Klabunde CN, Kahn KL, Weeks JC, Kiefe CL. Enrollment of lung and colorectal cancer patients in clinical trials. *Journal of Oncology Practice* 9(2): e40-47, March 2013. PMC3595449
137. Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, **Lee JY**, Darragh TM, Da Costa M, Panther L, Aboulafia D, Palefsky JM: Safety and efficacy of topical

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 16

- Cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. *AIDS* 27(4):545-51, February 2013. PMC3759510
138. Avins AL, **Lee JY**, Meyers CM, Barry MJ. Safety and toxicity of saw palmetto in the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Trial. *J Urol* 189(4): 1415-20, April 2013. PMC3716255
139. Taylor SN, Schwebke J, Lensing S, Lillis R, Mena LA, Nelson AL, Rinaldi A, Saylor L, McNeil L, **Lee JY**. Prevalence and treatment outcomes of cervicitis of unknown etiology. *Sexually Transmitted Diseases* 40(5): 379-85, May 2013. PMC3868214
140. Van Wagoner N, Morrow R, Lee J, Dixon P, Hook E. Serologic screening for herpes simplex virus type 2 in persons with human immunodeficiency virus. *Am J Med Sci* 346(2): 108-12, Aug 2013. PMC3723724
141. **Lee J**, Moore P, Kusek J, Barry M, Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. *J Alt Comp Med* 20(1): 48-52, January 2014. PMC3904527
142. Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, **Lee JY**, Kusek JW. Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia. *J Urol* 190(1):187-93, July 2013.
143. Wilkin T, **Lee JY**, Lensing SY, Stier EA, Goldstone SE, Berry MJ, Jay N, Aboulafia DM, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. High-grade anal intraepithelial neoplasia among HIV-1 infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. *HIV Clin Trials* 14(2):75-79, Mar-Apr 2013. PMC3676177
144. Koon HB, Krown SE, **Lee JY**, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Egorin MJ, Reid EG, Rudek MA, Dezube BJ, Noy A. Phase II trial of Imatinib in AIDS-associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042. *J Clin Oncol* 32(5): 402-8, February 2014. PMC3912327
145. **Lee JY**, Moore PC, Steliga MA. Do HIV-infected non-small cell lung cancer patients receive guidance-concordant care? *Medical care* 51(12): 1063-8. Dec 2013. PMC4047713
146. Barta SK, Xue X, Wang D, Tamari R, **Lee JY**, Mounier N, Kaplan LD, Ribera J-M, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyan C, Oriol A, Navarro J-T, Dunleavy K, Little R, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated Non-Hodgkin Lymphomas: a pooled analysis of 1546 patients. *Blood* 122(9): 3251-62, Nov 2013. PMC3821722
147. Kaplan SA, **Lee JY**, O'Neill EA, Meehan AG, Kusek JW. Prevalence of low testosterone and its relationship in body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. *The Aging Male* 16(4): 169-72, Dec 2013.
148. Klimberg VS, Ochoa D, Henry-Tillman R, Hardee M, Boneti C, Adkins LL, McCarthy M, Tummel E, **Lee J**, Malak S, Makhoul I, Korourian S. Long-term results of phase II ablation after breast lumpectomy added to extend intraoperative margins (ABLATE I) trial. *J Am Coll Surg* 18(4): 741-9, April 2014.
149. Rivers C, **Lee J**, Sharples N, Ledebner N, Schwebke J. ESwab as an optional collection device for use with the Affirm VPIII microbial test system. *J Clin Micro* 52(5):1698-1700, May 2014. PMC3993654

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 17

150. Apewokin S, Vyas K, Lester LK, Grazzuitti M, Haselow DT, Wolfe F, Roberts M, Bellamy W, Kumar NS, **Lee J**, Laudadio J, Wheeler JG, Bradsher R. Influenza A outbreak in an ambulatory stem cell transplant center. *Open Forum Infectious Diseases* 1(2):1-7, June 2014. PMC4281787
151. Hosseinipour M, Sweet K, Xiong J, Namarika D, Mwafongo A, Nyirenda M, Chiwoko L, Kamwendo D, Hoggman I, **Lee J**, Phiri S, Vahrson W, Damania B, Dittmer D. Viral profiling identifies multiple sub-types of Kaposi Sarcoma. *mBio* 5(5): e01633-14, September 23, 2014. PMC4173763.
152. Erickson SW, Raj VR, Stephens OW, Dhakal I, Chavan SS, Sanathkumar N, Coleman EA, **Lee JY**, Goodwin JA, Apewokin S, Zhou D, Epstein J, Heuck CJ, Vangsted AJ. Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma. *Blood* 124(12): 2001-3, September 18, 2014.
153. Barta FS, Xue X, Want D, **Lee JY**, Kaplan LD, Ribera J-M, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano J. ARL-IPI – a new prognostic score for AIDS-related lymphomas in the rituximab-era. *Haematologica*, 99(11): 1731-7, November 2014. PMC4222464
154. **Lee JY**, Klimberg VS, Bondurant KL, Phillips MM, Kadlubar SA. Cross-sectional Study to Assess the Association of Population Density with Predicted Breast Cancer Risk. *The Breast Journal* 20(6): 615-621, November/December 2014.
155. Coleman EA, **Lee JY**, Erickson SW, Goodwin JA, Beggs ML, Sanathkumar N, Zhou D, McKelvey KD, Raj VR, Apewokin S, Stephens O, Enderlin CA, Vangsted AJ, Reed PJ, Anaissie EJ. Chemotherapy-induced oral mucositis: 11 SNPs implicated in GWAS of 972 patients with multiple myeloma. *Supportive Care in Cancer* 23(3):841-9, March 2015. PMC4371856
156. McClelland RS, Balkus JE, **Lee J**, Anzala O, Kimani J, Schwebke J, Bragg V, Lensing S, Kavak L. Randomized trial of periodic presumptive treatment with high-dose intravaginal Metronidazole and Miconazole to prevent vaginal infections in HIV-negative women. *J Inf Dis* 211(12):1875-82, June 15, 2015. PMC4836721.
157. Noy A, **Lee J**, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnson N, Kaplan L. AMC048: Modified CODOX-M/IVAC-Rituximab is safe and effective for HIV-Associated Burkitt Lymphoma, *Blood* 126(2): 160-6, July 2015. PMC44697960.
158. Apewokin S, Coleman EA, Goodwin JA, **Lee JY**, Erickson SW, Sanathkumar N, Raj VR, Zhou D, McKelvey KD, Stephens O, Anaissie E. Contribution of *Clostridium Difficile* Infection to the Development of Lower Gastrointestinal Adverse Events during Autologous Stem Cell Transplantation. *Transplant Infectious Diseases* 17(4): 566-573, August 17, 2015.
159. Epeldegui M, **Lee JY**, Martinez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martinez-Maza O. Predictive value of cytokines and immune activation biomarkers in AIDS-related non-Hodgkin lymphoma treated with rituximab plus infusional EPOCH. *Clin Cancer Research* 22(2):328-36, January 2016. PMC4715998
160. Hernandez AL, Karthik R, Sivasubramanian M, Raghavendran A, Gnanomonv M, Lensing S, **Lee JY**, Kannangai R, Abraham P, Mathai D, Palefsky JM. Prevalence of

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 18

- anal HPV infection among HIV-positive men who have sex with men in India. *J Acquir Immune Defic Syndr* 71(4):437-43, April 2016.
161. Geisler WM, Unival A, **Lee JY**, Lensing SY, Johnson S, Perry RCW, Kadrnka M, Kerndt PR. Azithromycin versus doxycycline for urogenital chlamydia trachomatis infection. *N Engl J Med* 373: 252-2521, December 24, 2015. PMC4708266
 162. Kaplan SA, **Lee JY**, Meehan AG, Kusek JW: Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride, and Combination Therapy in Men with Benign Prostatic Hyperplasia: the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. *J Urol* 195(6):1825-9, June 2016.
 163. **Lee JY**, Malak SF, Klimberg VS, Henry-Tillman R, Kadlubar S: Change in Mammography Use Following the Revised Guidelines from the U.S. Preventive Services Task Force, *The Breast Journal* 23(2):164-68, March 2017.
 164. Bender Ignacio RA, **Lee JY**, Rudek MA, Dittmer DP, Ambinder RF, Krown SE: A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi's sarcoma: AIDS Malignancy Consortium trial 059, *JAIDS* 72(1):52-7, May 1, 2016. PMC4838493.
 165. Schwebke JR, **Lee JY**, Lensing S, Philip SS, Wiesenfeld HC, Seña AC, Trainor N, Acevado N, Saylor L, Rompala AM, Cook RL. Home screening for bacterial vaginosis to prevent sexually transmitted diseases. *Clin Infect Dis* 62(5):531-6, March 2016. PMC4741364
 166. Balkus JE, Manhart LE, **Lee J**, Onzala O, Kimani J, Schwebke J, Shafi J, Rivers C, Kabare E, McClelland RS. Periodic presumptive treatment for vaginal infections may reduce the incidence of bacterial sexually transmitted infections. *J Inf Dis* 213(12):1932-7, June 2016. PMC4878720
 167. Tummel E, Ochoa D, Korourian S, Betzold R, Adkins L, McCarthy M, Hung S, Kalkwarf K, Gallagher K, **Lee JY**, Klimberg VS. Does axillary reverse mapping prevent lymphedema after lymphadenectomy? *Ann Surg* 265(5):987-992, May 2017..
 168. Makhoul I, Griffin RJ, Siegel E, **Lee J**, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. High Circulating Tie-2 is Associated with Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. *American Journal of Clinical Oncology* 39(3):248-54, June 2016.
 169. Sparano JA, **Lee JY**, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Fitzgerald TJ, Kachnic L, Mitsuyasu R. Cetuximab plus Chemoradiotherapy for Human Immunodeficiency Virus-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial (AMC045). *J Clin Oncol* 35(7): 718-726, March 2017. PMC5455422.
 170. **Lee JY**, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT. Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy. *Journal of Cancer Epidemiology*, epub November 2, 2016. PMC5110893.
 171. Makhoul I, Todorova V, Siegel E, Erickson S, Dhakal I, Raj V, **Lee J**, Sorloff M, Griffin R, Henry-Tillman R, Klimberg S, Hutchins L, Kadlubar S. Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA are Associated with Pathologic

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 19

- Complete Response to Bevacizumab in Breast Cancer Patients. PLoS One 12(1):e0168550, January 3, 2017.
172. Jordan S, Gupta K, Ogendi B, Bakshi R, Kapil R, Press C, Sabbaj S, **Lee J**, Geisler W. The Predominant CD4+ Th1 cytokine elicited to chlamydia trachomatis infection in women is tumor necrosis factor alpha, not interferon-gamma. Clinical And Vaccine Immunology 24(4): e00010-17, April 5, 2017. PM5382828
 173. Bakshi RK, Gupta K, Jordan SJ, Brown LT, Press CG, Papp JR, Morrison SG, **Lee JY**, Morrison RP, Geisler WM. Immunoglobulin-based investigation of spontaneous resolution of chlamydia trachomatis infection. J Infect Dis 215(11): 1653-56, June 2017. PMC5853778.
 174. Kahn JA, **Lee J**, Belzer M, Palefsky JM. Most HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination. AIDS and Behavior, epub February 20, 2017. PMC5563486
 175. Royse K, El Chaier F, Amirian E, Hartman C, Krown S, Uldrick TS, **Lee JY**, Shepard Z, Chiao E. Disparities in Kaposi Sarcoma incidence and survival in the United States: 2000-2013. PLOS One 12(8): e0182750, August 2017. PMC5567503
 176. Ramos JC, Mitsuyasu R, Noy A, Rudek M, Cesarman E, Reid EG, Ambinder RF, Ratner L, Henry D, Moore PC, Sparanos JA, Aboulafia D, **Lee J**. Safety and Preliminary Efficacy of Vorinostat with R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clin Lymphoma Myeloma Leuk 18(3): 180-190. March 2018. PMC in progress.
 177. Tan CR, Barta SK, **Lee J**, Rudek MA, Sparano JA, Noy A. Antiretroviral therapy accelerates immune recovery in AIDS-lymphoma treated with EPOCH: a single trial comparison AMC034. Leukemia and Lymphoma, epub November 21, 2017: 1-10. PMC5962410.
 178. Wagner-Johnston ND, Lensing S, Noy A, Ratner L, Henry D, **Lee JY**, Silver S, Faham M, Ambinder RF. High Frequency of Identical Clonal Immunoglobulin DNA in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphoma: Prospective Multicenter Trial of the AIDS Malignancies Consortium (AMC 064). Leukemia and Lymphoma. December 2017; 58(12):2939-2942. PMC5867902.
 179. Ogendi BMO, Bakshi RK, Gupta K, Kapil R, Brown LT, Jordan SJ, Sabbaj S, Press CG, **Lee JY**, and Geisler WM. T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions. Microbes and Infection 20(3):176-184. March 2018. PMC5851839.
 180. Ogendi BMO, Bakshi RK, Sabbaj S, Brown L, **Lee JY**, Kapil R, Geisler WM. Distinct peripheral vs mucosal T-cell phenotypes in chlamydia-infected women. Am J Reprod Immunol. 2017 Dec;78(6). PMC5681419
 181. Seña AC, **Lee JY**, Schwebke J, Philip SS, Wiesenfeld HC, Rompalo AM, Cook RL, Hobbs MM: A silent epidemic: the prevalence, incidence and persistence of Mycoplasma genitalium among young, asymptomatic high-risk women in the United States.. Clinical Infectious Diseases, epub January 12, 2018.
 182. Snowden J, Darden P, Palumbo P, Saul P, **Lee J** for the IDeA State Pediatric Clinical Trials Network. The institutional development award states pediatric clinical trials

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 20

network: building research capacity among the rural and medically underserved. *Curr pin Pediatr* 30(2): 297-302, April 2018. PMC5927618.

183. Apewokin S, **Lee JY**, Goodwin JA, McKelvey KD, Stephens OW, Zhou D, Coleman EA. Host genetic susceptibility to *Clostridium difficile* infections in patients undergoing autologous stem cell transplantation: a genome-wide association study. *Support Care Cancer*, epub March 28, 2018.
184. Burkhalter J, Atkinson T, Holland S, Shuk E, Webb A, Rogers M, Berry-Lawhorn J, Goldstone S, Einstein M, Levine R, Wilkin T, Nicholas S, **Lee J**, Lubetkin, E, Taylor J, Cella D, Palefsky J. Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL): AMC-A02. *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research*, epub April 11, 2018.
185. Ellsworth GB, Lensing SY, Ogilvie CB, **Lee JY**; Goldstone SE, Berry-Lawhorn JM, Jay N, Stier EA, Logan JS, Einstein MH, Saah A, Mitsuyasu RT, Aboulafia D, Palefsky JM, Wilkin TJ. A Delayed Dose of Quadrivalent Human Papillomavirus Vaccine Demonstrates Immune Memory in HIV-1-infected Men. *Papillomavirus Res*. In press.

NON-PEER REVIEWED MANUSCRIPTS

186. Juhlin KD, **Lee JY**, Ragan DP: A MUMPS based survival analysis package. *Proceedings of the 1977 MUMPS User's Group Meeting*, Richard E Zapolin, editor, pp 61-64, December, 1977.
187. Ragan DP, **Lee JY**, Juhlin KD: Statistics - An interactive survival analysis package. *Proceedings of the Fifth Conference on Computer Applications in Radiology*, pp 389-400, June, 1977.
188. **Lee JY**: An interactive system for clinical trials. *Proceedings of the Third Annual Symposium on Computer Applications in Medical Care*, Rosalie Dunn, editor, pp 404-405, October, 1979.
189. Fondy EM, **Lee JY**: SEQRAN - An interactive sequential randomization system for clinical trials. *Proceedings of the SAS User's Group International (Hollywood Beach, FL)*, pp 775-780, March, 1984.
190. **Lee JY**, White JM: %SURVCOMP - SAS %MACRO for descriptive survival analysis. *Proceedings of the 1985 Meeting of the SAS User's Group International (Reno, Nevada)*, March, 1985.
191. **Lee JY**, Moore PC, Lensing SY. Sample size re-estimation using an internal pilot study with Poisson rates and adjustment to the nominal p-value. *Proceedings of the Joint Statistical Meetings, Washington, D.C.*, August 2009.

SUBMITTED:

1. Apewokin S, Lee J, Goodwin J, Owens S, McKelvey K, Zhou D, and Coleman A. Host Genetic Susceptibility to *Clostridium difficile* Infections in Patients Undergoing Autologous Stem cell Transplantation: A genome-wide association study. Submitted. T cell phenotypes in women with *Chlamydia trachomatis* infection and influence of treatment on phenotype distributions.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 21

2. Kahn J, Belzer M, Chi X, Lee J, Gaur A, Mayer K, Martinez J, Futterman D, Stier E, Paul M, Chiao E, Reirden D, Goldstone S, Martinez AO, Cachay E, Barroso L, Da Costa M, Wilson C, and Palefsky J: Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIVinfected men who have sex with men. A randomized clinical trial of infrared coagulation ablation versus active monitoring of intra-anal high-grade dysplasia in HIV-infected adults: An AIDS Malignancy Consortium trial
3. Goldstone, SE, Lensing SY, Stier E, Darragh T, Lee J, van Zante A, Jay N, Berry-Lawhorn MJ, Cranston RD, Mitsuyasu R, Aboulafia D, Palefsky JM. A randomized clinical trial of infrared coagulation ablation versus active monitoring of intra-anal high-grade dysplasia in HIV-infected adults: An AIDS Malignancy Consortium trial.

ABSTRACTS:

1. **Lee JY**, Rhode CA: Likelihood techniques for discrete distributions. Summaries of papers presented at the 136th Annual Meeting of the American Statistical Association: 96, 1976.
2. Perez CA, Reeves GI, Glasgow G, **Lee JY**: The role of the radiation therapy in the local and regional control of carcinoma of the breast. . Int J Radiat Oncol Biol Phys 2(Suppl 2): 99, 1977.
3. Perez CA, Braun L, **Lee JY**: Psychological reactions of patients to radiation therapy and the diagnosis of cancer. Int J Radiat Oncol Biol Phys 2(Suppl 2): 128, 1977.
4. **Lee JY**: Evaluation of phase I trial data using likelihood techniques. Summaries of papers presented at the Joint Statistical Meeting of the American Statistical Association, Biometrics Society, and Institute for Mathematical Statistics: 193, 1978.
5. Kumar S, **Lee JY**, Hernandez A, Crawford C, Goldring D: Baroreceptor function in juvenile primary hypertension. Pediatric Res 14:429, 1980.
6. Kurichety PR, Mill WB, Prasad SC, **Lee JY**: Radiation induced pericarditis in mantle irradiation: Analysis of causative factors. Int J Radiat Oncol Biol Phys 6:1366, 1980.
7. Manu P, Runge LA, **Lee JY**, Oppenheim AD: Perceived frequency of serious complications after "invasive" diagnostic procedures: Systematic biases of a physician population. Clin Res 31:300A, 1983.
8. LoBuglio AF, Wheeler R, Leavitt RD, Harvey EB, Holden HT, Haynes A, Rogers K, **Lee J** and Khazaeli M: Pharmacokinetics and immune response to chimeric mouse/human monoclonal antibody (Ch-17-1A) in man. Proceedings of the 1988 meeting of the American Society of Clinical Oncology 7:1111 (Abstract 425).
9. Weinsier R, **Lee J** and Darnell B: Comparison of physiologic extremes of high and low carbohydrate diets on fuel utilization and energy expenditure. Am J Clin Nutr 55 (3 Suppl):97, 1992.
10. Kusek JW, **Lee JY**, Agodoa LY, Kirk KA, Wright JT, Glassock R: Study design of the pilot phase the African American Study of Kidney Disease and Hypertension (AASK). Control Clin Trials 15 (3S): 1335, 1994.
11. **Lee JY**, Jensen B, Oberman A, Fletcher G, Fletcher B, Raczynski J: Adherence in the Training Levels Comparison Trial. Control Clin Trials 15(3S): 1145, 1994.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 22

12. Whelton P, Kusek J, **Lee J** and Faulkner M: Recruitment in the African American Study of Kidney Disease and Hypertension. *J Am Soc Nephrol* 5(3): 570, 1994.
13. **Lee J**, Bernhard S, Douglas M, Greene P, Kusek J, Norris K and Whelton P: Assessing medication adherence in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 16(3S):37S, 1995.
14. Whelton P, **Lee J**, Kopple J, Kusek J, Faulkner J and Charleston J: Challenge of minority recruitment in clinical trials: experience of the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 16(3S): 43S, 1995.
15. Kusek J, **Lee J**, Charleston J, Faulkner M, Levell B, Milligan S and Norris K: Reasons for joining and barriers to participation in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials* 16(3S): 42S, 1995.
16. **Lee J**, Mosher A, Gallis H, Panzer H and Sobel J: Comparison of participants and non-participants in a clinical trial of funguria. *Control Clin Trials* 18(3S): 121S, 1997.
17. Sobel JD, McKinsey D, Kauffman C, Zervos M, Vazquez JA and **Lee J**: Asymptomatic candiduria: A randomized double blind study of treatment with fluconazole and placebo. *Proceedings of the Infectious Diseases Society of America 35th Meeting*, abstract 12, page 73, September 1997.
18. Pappas PG, Rex JH, Hamill RJ, Larsen RA, Powderly WG, Horowitz H, Kauffman CA, Chapman SW, and **Lee J**: Current trends in nosocomial candidemia: results of a large multicenter study. *Proceedings of the Infectious Diseases Society of America 35th Meeting*, abstract 13, page 73, September 1997.
19. Martin M, Pisu M, **Lee J**, Fouad MA, Kiefe C. Life Extending Treatment at All Cost? 4th Biennial Cancer Survivorship Research Conference, Atlanta, Georgia, June 2008.
20. Murthy RK, Kvale EA, **Lee JY**, Taylor R, Nabors LB. Distress and quality of life in glioblastoma patients. *J Support Oncol* 5(8): 407, 2007.
21. Wen Y-j, Zhao W-z, Graziutti M, Ling W, **Lee J**, Van Rhee F, Barlogie B, Anaissie EJ. Baseline platelet count predicts outcome of invasive aspergillosis among neutropenic patients with multiple myeloma. *Blood* 112:4353, Nov 2008.
22. Badgwell BD, Pierce C, Broadwater JR, Westbrook K, Korourian S, David D, Hiatt K, **Lee J**, Klimberg S. Intraoperative sentinel lymph node analysis in melanoma. *Society of Surgical Oncology*. St. Louis, Missouri, March 2010.
23. **Lee JY**, Enoch K, Gibson R, Stewart C, Fincher R, Bland K, Thompson M, Klimberg VS, Henry-Tillman RS. Impact of mobile mammography among the medically underserved. *J Clin Oncol* 28 (suppl), e12027, Jun 2010.
24. Deeken JF, Mitsuyasu RT, Little RF, Ivy SP, Ambinder RF, Rudek MA, **Lee JY**, Moore PC, Mosby K, Dezube BJ. Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patient on ART. *American Society of Clinical Oncology*. Chicago, Illinois. June 2013.

POSTER EXHIBITS:

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 23

1. **Lee J**, Oberman A, Fletcher G, Sulentic J and Fletcher B: Training levels comparison (TLC) Trial design issues. Society for Clinical Trials, Toronto, Canada, May 1990.
2. Denning DW, Pappas PG, Kauffman CA, Hostetler JS, **Lee JY** and Stevens DA, and the NIAID Mycoses Study Group: Oral itraconazole therapy of invasive aspergillosis. InterScience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 1991.
3. **Lee JY**, Jensen B, Oberman A, Fletcher G, Fletcher B, Raczynski J: Adherence in the Training Levels Comparison Trial. Society for Clinical Trials, 1994.
4. Gallis H, Sobel J, Kauffman C, Karchmer A, McKinsey D, Mosher A and **Lee J**: A prospective multicenter surveillance study of funguria in hospitalized patients. Infectious Diseases Society of America meeting, October 1995.
5. Meredith R, Salter M, Kim R, Spencer S, Weppelmann B, Rodu B, Smith J and **Lee J**: Sucralfate for radiation mucositis: results of a double-blind randomized trial. American Society of Therapeutic Radiation Oncology, October 1995.
6. **Lee JY**, Smith DE, Cornell CE, Faulkner M, Kopple J, Kusek JW and Milligan S: Quality of life in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. American Society of Nephrology, November 1995.
7. Knoll GA, Tankersly MR, **Lee JY**, Julian BA and Curtis JJ: Renal transplantation improves survival of anti-HCV positive ESRD patients. American Society of Nephrology, 1996.
8. Kusek JW, **Lee JY**, Smith DE, Milligan S, Faulkner M, Cornell C, Kopple JD, Greene PG, and Agodoa LY. Quality of Life among clinical trial screens during baseline in the African American Study of Kidney Disease and Hypertension (AASK) pilot Study. International Society of Hypertension in Blacks, New Orleans, Louisiana, July 1996.
9. Kusek JW, **Lee JY**, Greene PG, Douglas M, Grim c, Kirk KA, Milligan S, Smith DE, Whelton PK, and Agodoa LY. Appointment attendance, pill counts and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension (AASK) pilot study. International Society of Hypertension in Blacks, New Orleans, Louisiana, July 1996.
10. Mulligan SA, Bostany CA, and **Lee JY**: Impact of double reading mammography in private practice setting. Radiological Society of North American annual meeting. Chicago, Illinois, December 1996.
11. Stevens D and **Lee J**: Analysis of compassionate use itraconazole of invasive aspergillosis by the NIAID Mycoses Study Group criteria. American Society for Microbiology, Miami Beach, Florida, May 1997.
12. **Lee J**, Mosher A, Gallis H, Panzer H and Sobel J: Comparison of Participants and non-participants in a clinical trial of funguria. Society of Clinical Trials, Boston, Massachusetts, July 1997.
13. Miles SA, Dezube B, **Lee J**, Groopman J, Saville W, Scadden D, Debruge J, Friedman-Kien and the AMC 002 Team. Oral LGD1057 is Active in AIDS Related Kaposi's Sarcoma: An AIDS Malignancies Consortium Trial (AMC-002). American Society of Clinical Oncology, Los Angeles, CA, May 1998.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 24

14. **Lee J**, Miles SA, Dezube B, Kaplan L, Groopman J, Saville W, Scadden D, Debruge J, Friedman-Kien A and the AMC 002 Team. Recruitment in a Two-Stage Phase II Trial of AIDS Kaposi's Sarcoma. 2nd National AIDS Malignancy Conference, Bethesda, MD, April 1998.
15. **Lee J**, Miles S, and Friedman-Kien A for the NCI AIDS Malignancies Consortium. Suspending Enrollment in a Two-Stage Phase II AIDS Malignancies Consortium Trial of AIDS Kaposi's Sarcoma Patients. Society for Clinical Trials, Atlanta, Georgia, May 1998.
16. Pappas PG, Rex JH, **Lee J**, Hamill R, Larsen R, Powderly W, Horowitz H, Hyslop N, Mangino J, Webster R, Thomas C and the NIAID Mycoses Study Group Candidiasis Subproject. Candidemia in the United States: Therapeutic Approaches and the Emergence of Non-albicans Candida species. Infectious Diseases Society of America, Denver, Colorado, November 1998.
17. Cox GM, Perfect JF, Stevens DA, Kauffman CA, **Lee JY** and the NIAID Mycoses Study Group. Hospital-based Survey of Aspergillosis. Infectious Diseases Society of America, Philadelphia, Pennsylvania, November 1999.
18. Rex JH, Ostrosky-Zeichner L, Pappas PG, Hamill RJ, Larsen RA, Horowitz H, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino J, **Lee J** for the NIAID-MSG Candidiasis Subproject. Antifungal Susceptibility Survey of 2000 Bloodstream Candida Isolates from the United States. Infectious Diseases Society of America, San Francisco, October 2001.
19. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz H, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino J, **Lee J** for the NIAID-MSG Candidiasis Subproject. Three Year Survey of Regional and Temporal Trends in Fluconazole (FLU) Resistance (R) Among Bloodstream Candida spp. Isolates from the United States. Infectious Diseases Society of America, San Francisco, October 2001.
20. Woodberry T, Henry L, O'Connor P, Davis J, **Lee J**, Kaplan L, Khayrallah M, Osmond D, Martin J, Scadden D, Brander C and the AIDS Malignancy Consortium. Mediated immune response to KSHV ORF65 and ORF73 in individuals with and without KS. 7th International AIDS Malignancy Conference, April 28-29, 2002. Bethesda, Maryland.
21. Miller LG, Man D, Lee C, **Lee JY**, Dismukes WE, Kauffman C and the NIAID Mycoses Study Group. Predictors of candiduria resolution in hospitalized patients: a prospective multi-center investigation. Accepted for presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2003.
22. **Lee J** for the AIDS Malignancy Consortium. Pain and appearance are related to response to treatment in AIDS-related Kaposi's sarcoma. 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2004.
23. Novak J, Wittke S, Haubitz M, Walden M, Moldoveanu Z, Nichols CR, Kirksey C, **Lee J**, Hall S, Brown R, Renfrow M, Matousovich K, Julian BA, Wyatt R, Tomana M, Mestecky J, Mischak H. Urinary protein analyses reveal patterns and biomarkers specific for IgA Nephropathy. American Society of Nephrology, Philadelphia, Pennsylvania, November 2005.
24. Chadburn A, Chen X, Hujek E, Tam W, Kaplan LD, Sparano JA, **Lee J**, Scadden DT, Chiu A, Knowles DM, Cesarman E and the AIDS Malignancies Consortium. Neither germinal center (GC) vs. non-germinal center (non-GC) phenotype nor FOXP1

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 25

- expression correlate with outcome in AIDS-associated diffuse large B-cell lymphoma (DLBCL): study of patients from AIDS Malignancies Consortium Trials 010 and 034. American Society of Hematology, Orlando, Florida, December 2006.
25. Suzuki H, Moldoveanu Z, Hall S, Brown R, Julian BA, Wyatt RJ, **Lee JY**, Tomana M, Tomino Y, Mestecky J, Novak J. Immunoglobulin-producing cell lines from patients with Henoch-Schoenlein Purpura (HSP) Nephritis secrete aberrantly-glycosylated IgA1 and anti-glycan IgG antibodies. American society of Nephrology, San Francisco, California, November 2007.
 26. Lechowicz MJ, **Lee J**, Dittmer D, Krown S, Said J, and Ambinder R: A pilot trial of valproic acid in patients with Kaposi's Sarcoma: a multi-center trial of the AIDS Malignancy Consortium. American Society of Hematology, Atlanta, Georgia, December 2007.
 27. Levine AM, **Lee J**, Kaplan L, Liebes L, Sparano JA: Efficacy and toxicity of concurrent rituximab plus infusional EPOCH is effective and not associated with increased toxicity in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 8527).
 28. Fouad M, **Lee J**, Kiefe C, Catalano P, Vogt T. Why do cancer patients rarely participate in clinical trials? *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 6561).
 29. **Lee JY**, Moore PC, Lensing SY. Sample size re-estimation for Poisson distributed variables with partial follow-up. Joint Statistical meetings, Washington, D.C., August 2009.
 30. Noy A, Kaplan L, **Lee J**. Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma (BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium. American Society of Hematology, New Orleans, Louisiana, December 2009.
 31. **Lee JY**, Foster HE Jr, McVary KT, Downey J, Stavris K, Meleth S, Kusek JW: Recruitment to a clinical trial of botanical therapy for benign prostatic hyperplasia. Society for Clinical Trials, Baltimore, Maryland, May 2010.
 32. Krown SE, Fingleton B, **Lee JY**, Egorin MJ, Koon HB: Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi's Sarcoma (KS): clinical and biological effects using a novel intra-patient control design. International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, Maryland, April 2010.
 33. Stier E, Goldstone S, Einstein M, Jay N, Berry M, Wilkin T, **Lee J**, Panther L, Aboulafia D, Palefsky J: Phase IIA trial of 1% topical cidofovir for treatment of high-grade perianal squamous intraepithelial neoplasia in HIV-infected men and women (AMC046). International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, Maryland, April 2010.
 34. Deeken JF, Mitsuyasu RT, Little RF, Ivy SP, Ambinder RF, Rudek MA, **Lee JY**, Moore PC, Mosby K, Dezube BJ. Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: an AIDS malignancy consortium study of sunitinib in patients on ART. American Society of Clinical Oncology. Chicago, Illinois, June 2010.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 26

35. **Lee JY**, Moore PC, Lensing SY. The Accuracy of Clinical Trial Inferences: the Saw Palmetto Experience. Presented at the Joint Statistical Meetings, Vancouver, Canada, August 2010.
36. Schwebke JR, Rompalo A, Taylor S, Seña AC, Martin DH, Lopez LM, Lensing S, **Lee JY**. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens – a randomized clinical trial. Accepted for presentation at the International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, Massachusetts, September 2010.
37. Lee J, Lensing S, Schwebke J. Retention of clinical trial participants in a study of non-gonococcal urethritis, a sexually transmitted infection. Society for Clinical Trials. Vancouver, Canada, May 2011.
38. Lee J and Kusek J. Association of baseline self-reported diabetes mellitus with 12 month change in lower urinary tract symptoms and prostate size: post-hoc analysis of the MTOPS study. American Urological Association meeting, Washington, D.C., May 2011.
39. Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, **Lee J**, Panther LA, Aboulaflia D, Palefsky JM. Phase IIA trial of 1% topical cidofoir for treatment of high-grade perianal squamous intraepithelial neoplasia in HIV-infected men and women (AMC046). International Papillomavirus Conference, Montreal, Canada, July 2010.
40. Noy A, Kaplan L, Lee J. Efficacy and tolerability of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and Atypical Burkitt Lymphoma (BL): Prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). *11th International Conference on Malignant Lymphoma*, Lugano, Switzerland. June 2011.
41. Lee JY, Henry-Tillman RS, Klimberg VS, Fincher R, Enoch K, Preston M, Jackson S, Kenney P. Use of patient navigation to improve diagnostic and treatment delays among patients with abnormal mammography results from a mobile unit. American Society of Clinical Oncology Breast Symposium, San Francisco, California, September 2011.
42. Lee J, Enoch K, Fincher R, Kenney P, Jackson S, Buie H, Strickland S, Preston M, Henry-Tillman R. Community partnerships are vital to the success of mobile mammography. American Public Health Association meeting, Washington, D.C., October 2011.
43. Lee JY and Moore PC. Prevalence of HIV in Medical Beneficiaries with Lung Cancer. International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, Maryland, November 2011.
44. Helfand BT, Sharp V, Williams OD, Foster H, Naslund M, Lee J, McVary KT. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. American Urological Association. Atlanta, Georgia, May 2012.
45. Kaplan S, **Lee J**, Kusek J. Long-term treatment with finasteride resulted in a greater improvement relative to placebo in urinary symptoms in men with enlarged prostates examined by deciles (≥ 30 mL, > 40 mL, ≥ 50 mL) compared to those with smaller prostates (< 30 mL); data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. American Urological Association. Atlanta, Georgia, May 2012.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 27

46. Crawford Ed, Sullivan KF, Arangua P, **Lee J**, Lensing S, O'Donnell CI. Comparison of the American Urological Association Symptom Index with a short version, UWIN, in a clinical phytotherapy trial. American Urological Association. Atlanta, Georgia, May 2012.
47. Garg M, **Lee JY**, Kachnic LA, Catalano PJ, Henry DH, Cooley TP, Ratner L, Wachsman W, Aboulafia DM, Benson AB, Palefsky J, Whittington R, Mitsuyasu RT, Sparano JA. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary results. American Society of Clinical Oncology. Chicago, Illinois. June 2012.
48. **Lee J**, Barry M, Kusek J for the CAMUS investigators. Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Society for Clinical Trials, Miami, Florida, May 2012.
49. Cook RL, Okafor C, Hillier S, Wiesenfeld H, Phillip S, Sena A, Lensing S, **Lee J**, Saylor L, Acevedo N, Schwebke J. Adherence to repeated home screening for bacterial vaginosis and STIs among young women participating in the BRAVO randomized clinical trial. STI and AIDS World Congress 2013, Vienna, Austria, July 2013.
50. Barta SK, Samuel M, Xue X, **Lee JY**, Mounier N, Kaplan LD, Ribera J-M, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Dunleavy K, Little RF, Remick SC, Goldfinger M, Noy A, Sparano JA. A pooled analysis of 1,546 patients with AIDS-related lymphoma (ARL): an assessment of prognostic factors by treatment era. American Society of Clinical Oncology. Chicago, Illinois. June 2013.
51. **Lee JY**, Moore PC, Steliga MA. Comorbidities: potential barriers to enrolling HIV-infected lung cancer cases on therapeutic clinical trials. International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, Maryland. November 2013.
52. Coleman EA, **Lee JY**, Erickson S, Goodwin J, Beggs M, Sanathkumar N, Zhou D, McKelvey K, Raj V, Apewokin S, Stephens W, Enderlin C, Vangsted AJ, Reed P, Anaissie EJ. Chemotherapy-induced oral mucositis: 11 SNPs implicated in GWAS of 972 patients with multiple myeloma. American Society of Hematology. New Orleans, Louisiana. December 2013.
53. Noy A, Kaplan L, **Lee JY**. A modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt-lymphoma (BL) demonstrates high cure rates and low toxicity. Prospective Multicenter Phase II trial of the AIDS Malignancy Consortium (AMC 048). American Society of Hematology. New Orleans, Louisiana. December 2013.
54. Kanakry JA, Shamay M, Kasamon YL, Li H, Gascoyne RD, Gordon LI, Noy A, Cesarman E, **Lee JY**, Horning SJ, Ambinder RF. Characterizing the CpG methylation of Epstein-Barr virus DNA in the plasma of patients with Hodgkin lymphoma and HIV-associated Burkitt lymphoma. American Society of Hematology. New Orleans, Louisiana. December 2013.
55. Makhoul I, Griffin RJ, Erickson S, Raj VR, Dhakal IB, Graves DA, **Lee JY**, Orloff MS, Siegel ER, Kadlubar SA. Germline genetic variants in ANGPT1 & 2 and FGF2 are associated with pathologic complete response to bevacizumab in breast cancer patients. American Association for Cancer Research. San Diego, California, April 2014.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 28

56. Palefsky J, Poongulali S, Lensing S, **Lee J**, DaCosta M, Jeeva AR, Iqbal S, Kumarasamy N. AMC054: safety and immunogenicity of the quadrivalent HPV vaccine in Indian HIV-infected women. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, March 2014.
57. Lee JY, Dhakal I, Kadlubar SA. Follow-up survey response rates in women at risk for breast cancer. Joint Statistical Meetings. Boston, Massachusetts, August 2014.
58. Balkus JE, Manhan LE, Anzala O, Schwebke J, Shafi J, Rivers C, Lee J, McClelland RS. Incidence of *Mycoplasma genitalium* infection among Kenyan and US women participating in the preventing vaginal infections trial. Infectious Diseases Society of Obstetrics and Gynecology. Stowe, Vermont, August 2014.
59. McClelland RS, Balkus J, Lee J, Anzala O, Kimani J, Schwebke J, Bragg V, Lensing S, Kavak L, Wolff P. . Preventing vaginal infections using periodic presumptive treatment with intravaginal metronidazole and miconazole: finding from a randomized, double-blind trial (The PVI Trial). Infectious Diseases Society of Obstetrics and Gynecology. Stowe, Vermont, August 2014.
60. Raghavendran A, Abraham P, Karthik R, Gnanamony M, Hernandez AL, Subramanian M, Lensing S, Lee JY, Kannangai R, Anand V, Kavi AR, Mathai D, Palefsky JM. AMC-060: Penile Human Papillomavirus Infection in Indian HIV-Positive Men Who Have Sex with Men. 29th International Papillomavirus Conference and Clinical & Public Health Workshops. Seattle, Washington, August 2014.
61. Apewokin S, Coleman E, Enderlin C, Goodwin J, Lee J, Erickson S, McKelvey K, Raj V, Kumar NS, Daohong Z. Genetic variants associated with the development of Clostridium Difficile infection during autologous stem cell transplantation. Infectious Diseases Society of America. Philadelphia, Pennsylvania, October 2014.
62. Lee JY, Malak S, Klimberg S, Henry-Tillman R, Kadlubar S, Racial Disparity of the Impact of the Change in Mammography Guidelines from the USPSTF. American Public Health Association, New Orleans, Louisiana, November 2014.
63. Ramos JC, Sparano JA, Moore PC, Lee JY, Rudek MA, Ambinder RF, Cesarman E, Noy A and Mitsuyasu RT. A sequential phase I/randomized phase II trial of Vorinostat and risk-adapted chemotherapy with rituximab in HIV-related B-cell non-Hodgkin's lymphoma. American Society of Hematology, San Francisco, California, December 2014.
64. Wagner-Johnston N, Lee JY, Silver S, Noy A, Mims MP, Pepin F, Moorhead M, Faham M, Ambinder RF. High frequency of identical lymphoma clones detected in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphomas: multicenter trial of the AIDS Malignancy Consortium (AMC 064). American Society of Hematology, San Francisco, California, December 2014.
65. Chiao EY, Rudek MA, Moore PC, Aboulafia DM, Ambinder RF, Baiocchi R, Shimabukuro KA, Broudy VC, Chuy JW, Lee JY, Little RF, Mitsuyasu RT, Haigentz M Jr. Phase I trial of Cabozantinib (SL184) for advanced solid tumors in persons with HIV infection: AIDS Malignancy Consortium (AMC) Trial 087 – Trial in progress. International Conference on Malignancies in AIDS and Other Immunodeficiencies, Washington, D.C., October 2015.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 29

66. Bender Ignacio R, Lee J, Rudek M, Dittmer D, Ambinder R, Krown S. A phase 1b/pharmacokinetic trial fo PTC299, a novel post-transcriptional VEGF inhibitor for AIDS-related Kaposi Sarcoma: AIDS Malignancy Consortium Trial 059. International Conference on Malignancies in AIDS and Other Immunodeficiencies, Washington, D.C., October 2015.
67. Lee JY, Lensing SY, Balkus J, Anzala O, Kimani J, Schwebke J, McClelland RS. Medication adherence in a study to prevent vaginal infections. Society for Clinical Trials. Montreal, Canada, May 2016.
68. Lee J, Burkhalter J, Botello-Harbaum M, Aboulafia D. Clinical trial participaton among HIV-infected persons with cancer. Society for Clinical Trials. Montreal, Canada, May 2016.
69. Seña AC, Wierzbicki MR, Lee JY, Cook JL, Schwebke JR. Natural history of bacterial vaginosis among young sexually active women. National STD Prevention Conference. Atlanta, Georgia, September 2016.
70. Lee JY, Lensing S, Perry R, Geisler W. Challenges of conducting a clinical trial in a youth correctional facility. Sociey for Clinical Trials. Portland, Oregon, May 2018.
71. Lensing S, Lee JY, Berry JM, Palefsky J. Challenges and successes in recruitment of HIV infected persons to a cancer prevention study. Sociey for Clinical Trials. Portland, Oregon, May 2018.

ORAL PRESENTATIONS:

1. Wade JS, Dockery BK, **Lee JY**, and Dismukes WE: Nystatin therapy for candida hypersensitivity Syndrome. Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, September, 1988.
2. Fletcher GF, Oberman A, Sheffield LT, **Lee JY**, Fletcher BJ, Felner JM, Nanda NC, Jensen BE, and Sulentic JA: Training level comparison study: influence of left ventricular function on maximal exercise test duration and maximal oxygen consumption. International Conference on Preventive Cardiology and the American Heart Association Council on Epidemiology, Washington, D.C., June, 1989.
3. Sulentic J, Dunnam L, Thiel J, Fletcher B, Oberman A, Fletcher G, Sheffield T, and **Lee J**: Training level comparison study: factors influencing exercise compliance. American College of Cardiology, Anaheim, California, March, 1989.
4. Raczynski JM, Oberman A, Fletcher GF, **Lee JY**, and Fletcher BJ: Training level comparison study - psychological effects of different exercise intensities in coronary artery disease patients. Conference in Cardiovascular Disease Epidemiology, San Diego, California, March, 1990.
5. Saleh M, Khazaeli M, Wheeler R, Rogers K, **Lee J** and LoBuglio, AF. Phase II trial of MoAb 17-1A and γ -INF in the treatment of metastatic colon cancer. American Association for Cancer Research, Washington, D.C., May, 1990.
6. Moores DWO, Ruckdeschel JC, **Lee JY**, Einhorn LH, Mandelbaum I and McKneally MF: Intrapleural bleomycin vs. tetracycline in the management of malignant pleural effusion. American Association for Thoracic Surgery, Toronto, Canada, May, 1990.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 30

7. Ruckdeschel J, Moores D, **Lee J**, Einhorn L, Mandelbaum I, Koeller J, Weiss G, Losada M and Keller J: Management of malignant pleural effusions (MPE): a randomized comparison of tetracycline and bleomycin. American Society of Clinical Oncology, Washington, D.C., May, 1990.
8. Sheffield LT, Oberman O, Fletcher G, Nanda N, Fletcher B, Sulentic J, Thiel J and **Lee J**: Training levels comparison study: response to treadmill and left lateral recumbent cycle exercise in men with coronary heart disease. International Conference on Preventive Cardiology and Meeting of the American Heart Association on Epidemiology, Washington, D.C., May, 1990.
9. Jansen B, **Lee J**, Nanda N, Fletcher B, Oberman A and Fletcher G: Training level comparison study: decreased left ventricular fraction improves with exercise training in patients with coronary artery disease. American Heart Association, Anaheim, California, November, 1991.
10. Dunbar S, Fletcher B, Jensen B, Raczynski J, **Lee J**, Oberman A and Fletcher G: Training level comparison study: predictive factors associated with exercise compliance. American Heart Association, Anaheim, California, November, 1991.
11. Fletcher GF, Oberman A, Nanda NC, Fletcher BJ, **Lee JY** and Dunbar SB: Training Levels Comparison Study: effects of high and low level exercise training on left ventricular ejection fraction in subjects with coronary artery disease. American College of Cardiology 42nd Annual Scientific Session, March 1993, Anaheim, California.
12. Sweeney ME, Fletcher GF, Oberman A, Nanda N, Clements SD, Fletcher BJ, Dunbar SB and **Lee JY**: Training Levels Comparison Study: comparison of two exercise echocardiograph methods for determining left ventricular ejection fraction. American College of Cardiology 42nd annual scientific session, March 1993, Anaheim, California.
13. Oberman A, Fletcher GF, **Lee JY**, Barbara BJ and Jensen BE: Training Level Comparison Study (TLC): one-year blood pressure findings. Third International Conference on Preventive Cardiology, Oslo, Norway, June 1993.
14. Jensen B, Fletcher B, Rupp J, Fletcher G and **Lee J**: Training Levels Comparison Study: effect of high and low intensity exercise on ventilatory threshold in men with coronary artery disease. American Association of Cardiovascular & Pulmonary Rehabilitation annual meeting, November 1993.
15. Perry G, Kell S, **Lee J**, Oberman A: Endurance exercise training improves cardiovascular performance in healthy older women. American Heart Association, Atlanta, Georgia, November 1993.
16. **Lee JY**: Patterns of short-term adherence in the African American Study of Kidney Disease and Hypertension. Third Annual Spring Clinical Nephrology Meetings of the National Kidney Foundation, April 1994.
17. Raczynski JM, Oberman A, Fletcher GF, **Lee JY** and Fletcher BJ: Training Levels Comparison Study: Psychological Effects of Different Exercise Intensities in Coronary Artery Disease Patients. Presented at the Society for Behavior Medicine meeting, April 1994.
18. Figueroa-Colon R, **Lee J**, Aldridge R and Alexander L: Obesity is Prevalent and Progressive in Birmingham School Children. Seventh International Congress on Obesity, August 1994.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 31

19. Whelton P, Kusek J, **Lee J** and Faulkner M: Recruitment in the African American Study of Kidney Disease and Hypertension. American Society of Nephrology, 1994.
20. Figueroa-Colon R, Franklin FA, **Lee J**, Aldridge R and Alexander L: Obesity with increased blood pressure is progressive and prevalent in elementary school-age children. American Federation for Clinical Research, New Orleans, Louisiana, February 1995.
21. **Lee J**, Bernard S, Douglas M, Greene P, Kusek J, Norris K and Whelton P: Assessing medication adherence in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Society for Clinical Trials, 1995.
22. Whelton P, **Lee J**, Kopple J, Kusek J, Faulkner J and Charleston J: Challenge of minority recruitment in clinical trials: experience of the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Society for Clinical Trials, 1995.
23. Kusek J, **Lee J**, Charleston J, Faulkner M, Levell B, Milligan S and Norris K: Reasons for joining and barriers to participation in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Society for Clinical Trials, 1995.
24. Fletcher GF, Oberman A, Fletcher BJ, Dunbar SB, **Lee J** and Rice CR: Training Level Comparison Study: Effects of exercise training intensity on insulin and glucose levels in coronary patients with "clustering" of risk factors. American College of Cardiology, March 1995.
25. Figueroa-Colon R, Franklin FA, Goran MI, **Lee JY**, Aldridge R and Weinsier RL: Reproducibility of resting energy expenditure (REF) in prepubertal females. American Society for Clinical Nutrition. San Diego, California, May 1995.
26. Sobel JD, McKinsey D, Kauffman C, Zervos M, Vazquez JA and **Lee J**: Asymptomatic candiduria: A randomized double blind study of treatment with fluconazole and placebo. Infectious Diseases Society of America, San Francisco, September 1997.
27. Pappas PG, Rex JH, Hamill RJ, Larsen RA, Powderly WG, Horowitz H, Kauffman CA, Chapman SW and **Lee J**: Current trends in nosocomial candidemia: results of a large multicenter study. Infectious Diseases Society of America, San Francisco, September 1997.
28. Friedman-Kien A, Dezube B, **Lee JY**, Groopman J, Saville W, Scadden D, Debruge J, Miles S and AMC 002 Team. Oral 9-cis Retinoic Acid is Active in AIDS Related Kaposi's Sarcoma: AIDS Associated Malignancy Consortium Study 002. 2nd National AIDS Malignancy Conference, Bethesda, Maryland, April 1998.
29. Schwartz HJ, Stevens DA, **Lee JY**, Jerome D, Catanzaro A and the NIAID Mycoses Study Group. A randomized double blind study of itraconazole (IZ) in allergic bronchopulmonary aspergillosis (ABPA): open label phase. 55th annual meeting of the American Academy of Allergy Asthma & Immunology, February 26-March 3, 1999, Orlando, Florida. Abstract #760.
30. Cianfrocca M, Cooley TP, **Lee J**, Scadden DT, Ratner L, Dezube BJ: Angiogenesis inhibitor Col-3 in the treatment of HIV-related Kaposi's Sarcoma: a phase I AIDS Malignancy Consortium Study. 4th International AIDS Malignancy Conference, May 16-18, 2000, Bethesda, Maryland.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 32

31. Walsh T, Pappas P, Winston D, Blumer J, Petersen F, Yanovich S, Raffalli J, Stiff P, Greenberg R, Donowitz G, Schuster M, Arndt C, Reinhardt J, Reboli A, Anaissie E, Hadley S, Garber G, Wingard J, Fioritoni G, **Lee J** and the NIAID Mycoses Study Group: Voriconazole versus Liposomal Amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: a randomized, international, multicenter trial. American Society of Hematology, San Francisco, California, December 2000.
32. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards J, Brass C, Chapman S, Horowitz H, Zervos M, McKinsey D, Kett D, Simmons B, **Lee J**, Mautner L, Chu TC, Panzer H and the Candidemia Study Group. A Randomized & Blinded Multicenter Trial of High-Dose Fluconazole (F) + Placebo (P) vs. F + Amphotericin B (A) as Treatment of Candidemia in Non-Neutropenic Patients. International Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 2001.
33. Noy A, Gill P, Scadden D, **Lee J**, Dezube B, Aboulafia D, Tulpule A, Walmsley S for the AIDS Malignancy Consortium and IM862 Team. Angiogenesis Inhibitor IM862 is Ineffective against AIDS-KS in a Randomized, Placebo Controlled Trial. 6th International AIDS Malignancy Conference, April 22-24, 2002. Bethesda, Maryland.
34. Lin L, Kaplan L, **Lee J**, Chadburn A, Cesarman E, Herman JG, Ambinder RF and the AIDS Malignancy Consortium. Monitoring Epstein - Barr virus Load in Peripheral Blood in AIDS-Related Lymphoma Patients: An AIDS Malignancy Consortium Laboratory Study. American Society of Hematology Meeting, December 2002.
35. Kaplan LD, **Lee J**, Caligiuri M, Von Roenn J, Levine A, Harrington W and Scadden D for the AIDS Associated Malignancies Consortium. A randomized phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with or without Rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS Malignancies Consortium Study 010. American Society of Clinical Oncology Meeting, Chicago, IL, June 2003.
36. Kaplan LD, **Lee J**, Scadden DT. No benefit from Rituximab in a randomized phase III trial of CHOP with or without Rituximab for patients with HIV-associated non-Hodgkin's lymphoma: Updated data from the AIDS Malignancies Consortium Study 010. American Society of Hematology Meeting, San Diego, CA, December 2003.
37. Robbin ML, Oser RL, **Lee JY**, Heudebert GR, Mennemeyer ST. Randomized clinical trial comparison of ultrasound surveillance and clinical monitoring on Arteriovenous Graft Outcomes. Annual meeting of the American Society of Nephrology, Philadelphia, Pennsylvania, November 2005.
38. Moldoveanu Z, Wyatt RJ, Novak J, **Lee J**, Julian BA, Tomana M, Mestecky J. Elevated serum creatinine concentration of *Helix aspersa* Lectin-binding IgA1 (HAA-IgA1) in pediatric patients with IgA Nephropathy (IgAN). Annual meeting of the American Society of Nephrology, Philadelphia, Pennsylvania, November 2005.
39. Sparano JA, **Lee JY**, Kaplan LD. Randomized phase II trial of infusional EPOCH chemotherapy given concurrently or sequentially with rituximab in HIV-associated lymphoma (AMC034). International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, Maryland, October 2006.

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 33

40. **Lee JY** for the CAMUS Investigators. Re-design of the NIH Complementary and Alternative Medicine for Urological Symptoms Trial Based on Results from Another NIH-Supported Trial. Society for Clinical Trials, Atlanta, Georgia, May 2009.
41. Barta SK, **Lee JY**, Sparano JA, Kaplan LD, Noy A for the AIDS Malignancy Consortium. Pooled analysis of AIDS Malignancy Consortium trials evaluating Rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin's lymphoma. International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, Maryland, April 2010.
42. Noy A, Kaplan L, Lee J, Cesaman E, Tam W. Modified dose intensive R-CODOX – M/IVAC for HIV-associated Burkitt (BL) (AMC048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 Expression. International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, Maryland, November 2011.
43. Deeken JF, Rudek MA, Moore PC, Aboulafia D, Sullivan R, Gerecitano J, Cianfrocca M, Henry D, Ratner L, Dezube B, Mosby K, Tibbals M, Little RF, Ivy SP, Mitsuyasu RT. A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS Malignancy Study 061. International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, Maryland, November 2011.
44. Epeldegui M, Widney DP, Martinez AC, Regidor D, Magpantay L, Mitsuyasu M, Sparano JA, Lee JY, Ambinder RF, Martinez-Maza O. Serum levels of several molecules that are associated with B cell activation and inflammation are elevated in AIDS-associated non-Hodgkin's lymphoma (AIDS-NHL) and predict response to treatment. International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, Maryland, November 2011.
45. Barta SK, Xue X, Ramari R, Lee JY, Mounier N, Kaplan LD, Ribera J-M, Spina M, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Navarro J-T, Dunleavy K, Little RF, Ratner L, Morgades M, Garcia O, Sparano JA. A pooled analysis of 1,144 patients with HIV-associated lymphoma: assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcome. American Society of Clinical Oncology. Chicago, Illinois. June 2012.
46. Wilkin T, Lensing S, Einstein M, Lee J, Goldstone S, Stier EA, Berry M, Jay N, Mitsuyasu R, Palefsky J. Quadrivalent HPV vaccine induced immune memory in HIV-infected men. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. March 2014.
47. Stier EA, Lee JY, Lensing S, Jay N, Berry-Lawhorn JM, Einstein M, Palefsky J, Wilkin T, Goldstone S, Chiao E. Anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive (HIV+) women, prevalence and risk factors: AIDS Malignancy Consortium (AMC) 084. International Anal Neoplasia Society, San Francisco, California, November 2016.
48. Wiley DJ, Chiao E, Lee J, Deshmukh AA, Cantor SB, Palefsky J, Stier E. Multiple-test anal cancer screening strategies improve anal HSIL-detection in HIV+ women and MSM: Report of Two Trials. International Anal Neoplasia Society, San Francisco, California, November 2016.
49. Goldstone S, Stier E, Lensing S, Jay N, Berry M, Cranston R, Darragh T, Lee J, Aboulafia D, van Zante A, Mitsuyasu R, Palefsky J, and Wilkin T. An AIDS Malignancy

CURRICULUM VITAE

Jeannette Y. Lee, Ph.D.

Page - 34

Consortium Randomized Clinical Trial of Infrared Coagulation (IRC) Ablation versus Deferred Treatment of Intra-Anal High Grade Squamous Intraepithelial Lesions (HSIL) in HIV-infected Subjects: Preliminary Results. International Anal Neoplasia Society, San Francisco, California, November 2016.

50. Battle B, Malak SF, Dhakal I, Lee J, Keith N, Fuhrman B. Association of volumetric mammographic density measures with breast cancer risk in 5,746 women. Radiological Society of North America, Chicago, Illinois, November 2016.
51. Reid E, Looney D, Maldarelli F, Noy A, Henry D, Aboulaflia D, Ramos JC, Sparano J, Ambinder R, Lee J, Mitsuyasu R, Wachsman W. AMC053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. American Society of Hematology, San Diego, California, December 2016.